-
公开(公告)号：US20220002665A1
公开(公告)日：2022-01-06
申请号：US17279247
申请日：2019-10-11
Applicant: KoBioLabs, Inc.
Inventor： Gwang Pyo KO , Hyo Shin YOON , Chung Hwan CHO , Hyun Ju YOU , Tae Wook NAM
Abstract: The present invention relates to Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and use thereof, specifically, a composition for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, comprising the strain, or a culture solution thereof, etc. or a B2UM07 protein isolated therefrom as an active ingredient, and use thereof for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, and a method of suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases using the same are provided. Through this, among the anti-obesity effects, not only weight reduction and glucose homeostasis regulation, but also the effect on brown fat and the effect of secreting appetite regulating hormones are exhibited.
-
公开(公告)号：US20220276246A1
公开(公告)日：2022-09-01
申请号：US17626632
申请日：2020-07-30
Applicant: KoBioLabs, Inc.
Inventor： Gwang Pyo KO , Won KIM , Hyun Ju YOU , Giljae LEE
IPC: G01N33/569
Abstract: The present invention relates to a kit for predicting or diagnosing the degree of risk of disease, a method for providing information for predicting or diagnosing the degree of risk of disease, a method for screening a therapeutic agent of disease, and a pharmaceutical composition for prevention or treatment of disease, for nonalcoholic fatty liver disease. Specifically, through the kit for predicting or diagnosing of the present invention, the degree of risk of nonalcoholic fatty liver disease can be effectively predicted or diagnosed, and in particular, the predictive value and significance of information provision in non-obese subjects are excellent. Therefore, by providing effective information on nonalcoholic fatty liver disease through this, it can be effectively used to prevent or treat the corresponding disease. In addition, the pharmaceutical composition for prevention or treatment of the present invention may be effectively used for treatment of nonalcoholic fatty liver disease.
-
公开(公告)号：US20220257669A1
公开(公告)日：2022-08-18
申请号：US17626628
申请日：2020-07-30
Applicant: KoBioLabs, Inc.
Inventor： Gwang Pyo KO , Won KIM , Hyun Ju YOU , Giljae LEE , Bo-Ram CHO
IPC: A61K35/74 , C12N1/20 , A23L33/135 , A61P1/16
Abstract: The present invention relates to a composition for preventing, alleviating or treating liver injury, for example, nonalcoholic fatty liver, and more specifically, it relates to a composition for preventing or treating liver injury comprising a Ruminococcus spp. strain.
-
4.发明申请公开(公告)号：US20180117100A1
公开(公告)日：2018-05-03
申请号：US15566352
申请日：2016-03-24
Applicant: KoBioLabs, Inc.
Inventor： Gwang Pyo KO , Hyun Ju YOU , Bo Mi KWON
IPC: A61K35/747 , C12R1/225 , A61P31/04 , A61P31/10 , A61P31/20 , A61P15/02 , A23L33/00 , A23L33/135 , A23L2/52 , A23C9/123
CPC classification number: A61K35/747 , A23C9/1234 , A23L2/52 , A23L33/135 , A23L33/40 , A23V2002/00 , A23Y2220/00 , A23Y2220/35 , A23Y2220/37 , A23Y2220/41 , A61P15/02 , A61P31/04 , A61P31/10 , A61P31/20 , C12R1/225
Abstract: The present invention relates to a novel Lactobacillus sp. isolation strain having an activity to inhibit the growth of vaginitis pathogens, and a pharmaceutical composition, a health functional food, and a cleansing product, comprising the strain as an active ingredient. Therefore, the present invention exhibits an effect of inhibiting the growth of Sneathia spp. pathogens associated with the infection with human papillomavirus (HPV) and the incidence of bacterial vaginitis, Gardnerella vaginalis as a vaginitis pathogen, and Candida albicans as a causative bacteria of Candidal vaginitis, and an effect of recovering and maintaining the vaginal microflora, and thus can be used for the prevention and treatment of female vaginitis.
-
-
-
Search Results
4
records
(took 0.013 seconds)
